David Slack
Vorstandsvorsitzender bei Cend Therapeutics, Inc.
Vermögen: 7 028 $ am 30.04.2024
Profil
David Slack is currently the President, Chief Executive Officer & Director at Cend Therapeutics, Inc. He is also the Chairman at Lisata Therapeutics Australia Pty Ltd.
Previously, he held positions such as Director-Technology Alliances & Licensing at Aventis Pharmaceuticals, Inc. and Rhone-Poulenc Rorer Pharmaceuticals, Inc. He was also the Vice President-Business Development at Ionis Pharmaceuticals, Inc. and the Chief Business Officer at Viracta Subsidiary, Inc. Additionally, he worked as a Principal at DS Lifescience Consulting.
Mr. Slack's education includes an undergraduate degree from California State University-Sacramento and an MBA from Monterey Institute of International Studies.
Bekannte Unternehmensbeteiligungen
| Unternehmen | Datum | Anzahl der Aktien | Bewertung | Datum der Bewertung |
|---|---|---|---|---|
| 29.04.2024 | 2 642 ( 0,03% ) | 7 028 $ | 30.04.2024 |
Aktive Positionen von David Slack
| Unternehmen | Position | Beginn |
|---|---|---|
Cend Therapeutics, Inc.
 Cend Therapeutics, Inc. BiotechnologyHealth Technology Cend Therapeutics, Inc. is a biopharmaceutical company, which engages in the development of therapies for solid tumor cancers. Its offers CendR Platform, which provides a targeted tissue penetration capability to specifically enhance drug delivery to tumors. Its lead compound CEND-1 seeks out tumors and activates the CendR transport pathway. The company was founded by Erkki Ruoslahti in 2016 and is headquartered in San Diego, CA. | Vorstandsvorsitzender | 08.07.2020 |
| Lisata Therapeutics Australia Pty Ltd. | Vorsitzender | - |
Ehemalige bekannte Positionen von David Slack
| Unternehmen | Position | Ende |
|---|---|---|
| LISATA THERAPEUTICS, INC. | Präsident | 01.05.2023 |
| DS Lifescience Consulting | Corporate Officer/Principal | 01.03.2021 |
Viracta Subsidiary, Inc.
 Viracta Subsidiary, Inc. BiotechnologyHealth Technology Viracta Subsidiary, Inc. engages in the development of proprietary viral gene activation therapy to address cancers associated with the Epstein-Barr virus. Its platform is designed as a targeted approach to treat a range of viral-associated cancers and other serious diseases. The company was founded by Ronald J. Berenson, Douglas V. Faller, George C. Hillman, Thalia Papayannopoulou, Susan P. Perrine, George Stamatoyannopoulos, and Robert Williams and is headquartered in Cardiff, CA. | Corporate Officer/Principal | 01.07.2020 |
| IONIS PHARMACEUTICALS, INC. | Corporate Officer/Principal | 01.01.2004 |
| Rhone-Poulenc Rorer Pharmaceuticals, Inc. | Corporate Officer/Principal | 01.01.2000 |
Ausbildung von David Slack
| California State University-Sacramento | Undergraduate Degree |
| Monterey Institute of International Studies | Masters Business Admin |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Börsennotierte Unternehmen | 2 |
|---|---|
| IONIS PHARMACEUTICALS, INC. | Health Technology |
| LISATA THERAPEUTICS, INC. | Health Technology |
| Private Unternehmen | 6 |
|---|---|
Aventis Pharmaceuticals, Inc.
 Aventis Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Aventis Pharmaceuticals, Inc. develops, manufactures and markets pharmaceutical products. The company was founded in 1950 and is headquartered in Bridgewater, NJ. | Health Technology |
| Rhone-Poulenc Rorer Pharmaceuticals, Inc. | |
Viracta Subsidiary, Inc.
Viracta Subsidiary, Inc. BiotechnologyHealth Technology Viracta Subsidiary, Inc. engages in the development of proprietary viral gene activation therapy to address cancers associated with the Epstein-Barr virus. Its platform is designed as a targeted approach to treat a range of viral-associated cancers and other serious diseases. The company was founded by Ronald J. Berenson, Douglas V. Faller, George C. Hillman, Thalia Papayannopoulou, Susan P. Perrine, George Stamatoyannopoulos, and Robert Williams and is headquartered in Cardiff, CA. | Health Technology |
Cend Therapeutics, Inc.
Cend Therapeutics, Inc. BiotechnologyHealth Technology Cend Therapeutics, Inc. is a biopharmaceutical company, which engages in the development of therapies for solid tumor cancers. Its offers CendR Platform, which provides a targeted tissue penetration capability to specifically enhance drug delivery to tumors. Its lead compound CEND-1 seeks out tumors and activates the CendR transport pathway. The company was founded by Erkki Ruoslahti in 2016 and is headquartered in San Diego, CA. | Health Technology |
| Lisata Therapeutics Australia Pty Ltd. | |
| DS Lifescience Consulting |
